A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer
K. A. Lopatina,
S. G. Krylova,
E. A. Safonova,
E. P. Zueva,
D. A. Kulagina,
А. A. Churin,
T. I. Fomina,
S. V. Sysolyatin https://doi.org/10.21294/1814-4861-2020-19-2-76-81
Abstract
Purpose: to study gastrotoxic and ulcerogenic effects of a long-term administration of a newly synthesized compound from the hexaazaisowurzitan (thiowurtzine) series in rats, as well as to assess its effect on the transplantable tumor in mice.
Material and Methods. Lewis lung carcinoma was transplanted into mice, and thiowurtzine was prescribed for a long course together with cyclophosphamide. In the terminal stage of tumor development the mass of the primary node, the number and area of metastases in the lungs of mice were measured. Histological sections of the stomach were studied in rats after a 90-day administration of thiowurtzine.
Results. Thiowurtzine at therapeutic dosages of 50 and 100 mg/kg for a course of 19 days potentiated the effect of cyclophosphamide to inhibit tumor dissemination and exerted a direct antitumor effect in mice with lewis lung carcinoma. A dose of 1000 mg/kg for 90 days did not cause ulcerogenic action of thiowurtzine.
Conclusion. The absence of a stimulating effect on tumor growth in animal experiments and intactness in relation to the gastric mucosa during chronic administration of thiowurtzine allow us to recommend this innovative analgesic for clinical study as a concomitant analgesia in cancer patients.
Supporting agencies: The study was carried out within the framework of the State Assignment № 0550-2019-0013 «Search and development of medicines of natural and synthetic origin, including those on the basis of genomic, postgenomic, bio- and nanotechnologies» with financial support from the Federal Target Program «Development of the pharmaceutical and medical industries of the Russian Federation» for the period until 2020 and beyond», state contract of August 15, 2017 No. 14.N08.11.0179 «Preclinical studies of a medicinal product based on hexaazaisowurtzitane derivatives for the treatment ofpain of various etiologies»
About the Authors
K. A. Lopatina
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Ksenia A. Lopatina - PhD, Researcher, Laboratory of Oncologic Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): N-4500-2015.
3, Lenina ave., 634028, Tomsk
S. G. Krylova
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Svetlana G. Krylova - DSc, Principal Researcher, Laboratory of Oncologic Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): C-8023-2017.
3, Lenina ave., 634028, Tomsk
E. A. Safonova
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Elena A. Safonova - PhD, Researcher, Laboratory of Oncologic Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): P-3174-2015.
3, Lenina ave., 634028, Tomsk
E. P. Zueva
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Elena P. Zueva - Professor, Head of Laboratory of Oncologic Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): C-6719-2017.
3, Lenina ave., 634028, Tomsk
D. A. Kulagina
Institute for Problems of Chemical and Energetic Technologies of the Siberian Branch оf the Russian Academy of Sciences
Russian Federation
Russian Federation
Daria A. Kulagina - Researcher, Medical Chemistry Department, Researcher ID (WOS): Q-2359-2017.
1, Socialisticheskaya str., 1659322, Biysk
А. A. Churin
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Alexey A. Churin - DSc, Head of Drug Toxicology Department, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): J-3206-2017.
3, Lenina ave., 634028, Tomsk
T. I. Fomina
Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Tatiana I Fomina - PhD, Senior Researcher, Drug Toxicology Department, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Researcher ID (WOS): J-3824-2017.
3, Lenina ave., 634028, Tomsk
S. V. Sysolyatin
Institute for Problems of Chemical and Energetic Technologies of the Siberian Branch оf the Russian Academy of Sciences
Russian Federation
Russian Federation
Sergey V. Sysolyatin - DSc, Director, Researcher ID (WOS): H-9688-2014.
1, Socialisticheskaya str., 1659322, Biysk
References
1. Abuzarova G.R. Cancer pain: facets of a problem. Medical Council. 2018; 19: 97-100. (in Russian). doi: 10.21518/2079-701X-2018-10-97-100.
2. Paravina E.V Pain medications in oncology. Consilium Medicum. 2014; 10: 53-56. (in Russian).
3. PakhomovaI.G., KuchminA.N., PavlovaE.Yu. Nonsteroidal anti-inflammatory drugs in acute pain: consensus of efficacy and safety. Russian Medical Journal. 017; 21: 1537-1542. (in Russian).
4. Kaminskaya I.A., Tyurenkov I.N. Administrative and organizational aspects of functioning of the system of availability narcotic and psychotropic medicinal preparations for patients who need them. Pharmacy & Pharmacology. 2016: 6(4): 72-83. (in Russian). doi: 10.19163/2307-9266-2016-72-83
5. Zhdanov V.V., Dygay A.M., Lopatina K.S., Zueva E.P., Razina T.G., Malykhin V.V., Sysolyatin S.V., Amosova E.N., Krylova S.G., KalashnikovA.I., Rybalkina O.Yu., VorozhtsovA.B., ZhukovA.S. 4-(3,4-dibromothiophene carbonyl)-2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazat etracyclo[5,5,0,03,11,05,9]dodecane as analgesic agent and method for production thereof. Patent № 2565766 of the Russian Federation, IPC C07D 487/22, A61P 29/00 № 2014146024/04; Declared 17 Nov 2014. Publ. 10.20.2015, Bull. No 29. (in Russian).
6. Krylova S.G., Povetieva T.N., Zueva E.P., Suslov N.I., Amosova E.N., Razina T.G., Lopatina K.A., Rybalkina O.Yu., Nesterova Yu.V., Afanasyeva O.G., Kiseleva E.A., Sysolyatin S.V., Kulagina D.A., Zhdanov V.V. Analgesic activity of hexaazaisowurtz-itane derivatives. Bulletin of Experimental Biology and Medicine. 2018; 10(166): 451-456. (in Russian).
7. KhabrievR.U. Guidelines for the experimental (preclinical) study of new pharmacological substances. Moscow, 2005. 832 p. (in Russian).
8. Lakin G.F. Biometry. Moscow, 1990. 352 p. (in Russian).
Review
For citations:
Lopatina K.A., Krylova S.G., Safonova E.A., Zueva E.P., Kulagina D.A., Churin А.A., Fomina T.I., Sysolyatin S.V. A new analgesic agent based on hexaazaisowurzitan: feasibility of using in managing patients with cancer. Siberian journal of oncology. 2020;19(2):76-81. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-2-76-81
Views:
1029
Email this article 
